We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Lyme Disease Distinguished from Chronic Fatigue Syndrome

By LabMedica International staff writers
Posted on 03 Mar 2011
Unique proteins in spinal fluid can distinguish between patients suffering from neurologic post treatment Lyme disease (nPTLS) and those with the Chronic Fatigue Syndrome (CFS).

Investigators found that both conditions involve the central nervous system and that protein abnormalities in the central nervous system are causes and/or effects of both conditions, which present with similar clinical symptoms.

Spinal fluid was analyzed from three groups of people. More...
One group consisted of 43 patients who fulfilled the clinical criteria for Chronic Fatigue Syndrome (CFS). The second group consisted of 25 patients who had been diagnosed with, and treated for, Lyme disease but did not completely recover. The third group consisted of 11 healthy control subjects.

The fluids were analyzed using high-powered mass spectrometry and protein separation techniques. Each group had more than 2,500 detectable proteins. The team discovered that 738 proteins were identified only in CFS but not in either healthy normal controls or in patients with nPTLS; 692 proteins were found only in the nPTLS patients.

The study team was led by Steven E. Schutzer, MD, of the University of Medicine and Dentistry of New Jersey (Newark, NJ, USA), and Richard D. Smith, PhD, of Pacific Northwest National Laboratory (Richland, WA, USA). The findings were, published in the February 23, 2011 edition of the journal PLoS ONE.

According to Dr. Schutzer, spinal fluid proteins can probably be used as a marker of disease. "One next step will be to find the best biomarkers that will give conclusive diagnostic results," he said. "In addition, if a protein pathway is found to influence either disease, scientists could then develop treatments to target that particular pathway."

Related Links:
University of Medicine and Dentistry of New Jersey
Pacific Northwest National Laboratory




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.